PDF(Pubmed)
Abstract：
Advanced glycation end products (AGEs) are involved in the development of several age-related complications. The protective role of soluble receptors for AGEs (sRAGE) against deleterious effects of AGEs has been indicated in several studies. However, findings on the association of AGEs or sRAGE with mortality are equivocal. In this meta-analysis we aimed to present a quantitative estimation of the association between circulating AGEs or sRAGE and all-cause or cardiovascular disease (CVD) mortality. A comprehensive literature search was performed to determine relevant publications through the online databases including PubMed, Scopus, and Web of Science up to 29 November 2020. Prospective observational studies assessing the association between circulating AGEs or sRAGE and all-cause or CVD mortality were included. Seven studies with a total of 3718 participants and 733 mortality cases (345 CVD deaths) were included in the meta-analysis for assessing the association between circulating AGEs and mortality. Our results showed that higher circulating AGEs were associated with increased risk of all-cause (pooled effect measure: 1.05; 95% CI: 1.01, 1.09; P = 0.018, I2 = 77.7%) and CVD mortality (pooled effect measure: 1.08; 95% CI: 1.01, 1.14; P = 0.015, I2 = 80.2%), respectively. The association between sRAGE and mortality was assessed in 14 studies with a total of 16,335 participants and 2844 mortality cases (419 CVD deaths). Serum concentrations of sRAGE were not associated with the risk of all-cause mortality (pooled effect measure: 1.01; 95% CI: 1.00, 1.01; P = 0.205, I2 = 75.5%), whereas there was a significant link between sRAGE and the risk of CVD mortality (pooled effect measure: 1.02; 95% CI: 1.00, 1.04; P = 0.02, I2 = 78.9%). Our findings showed that a higher serum AGE concentration was associated with increased risk of all-cause and CVD mortality. In addition, higher circulating sRAGE was related to increased risk of CVD mortality. This review was registered at PROSPERO as CRD42021236559.
摘要：
晚期糖基化终产物（AGEs）参与了几种与年龄相关的并发症的发展。在一些研究中已经表明了AGEs的可溶性受体(sRAGE)对AGEs的有害作用的保护作用。然而,关于AGEs或sRAGE与死亡率关联的研究结果是模棱两可的.在这项荟萃分析中，我们旨在对循环AGEs或sRAGE与全因或心血管疾病（CVD）死亡率之间的相关性进行定量评估。通过包括PubMed在内的在线数据库进行了全面的文献检索，以确定相关出版物。Scopus,和WebofScience截至2020年11月29日。纳入评估循环AGEs或sRAGE与全因或CVD死亡率之间关联的前瞻性观察性研究。7项研究共3718名参与者和733例死亡病例（345例CVD死亡）纳入荟萃分析，以评估循环AGEs与死亡率之间的关系。我们的结果表明，较高的循环AGEs与全因风险增加相关（合并效应测量值：1.05；95％CI：1.01，1.09；P=0.018，I2=77.7％）和CVD死亡率（合并效应测量值：1.08；95％CI：1.01，1.14；P=0.015，I2=80.2％），分别。在14项研究中评估了sRAGE与死亡率之间的关联，共有16,335名参与者和2844例死亡病例（419例CVD死亡）。sRAGE的血清浓度与全因死亡率的风险无关（合并效应测量：1.01；95％CI：1.00，1.01；P=0.205，I2=75.5％），而sRAGE与CVD死亡风险之间存在显著关联(合并效应测量值:1.02;95%CI:1.00,1.04;P=0.02,I2=78.9%).我们的发现表明，较高的血清AGE浓度与全因和CVD死亡率的风险增加有关。此外,较高的循环sRAGE与CVD死亡率风险增加相关.这篇评论在PROSPERO注册为CRD42021236559。
